Quanterix

One Kendall Square
Building 1400W, 2nd Floor
Cambridge
Massachusetts
02139
United States

Tel: 617-301-9400
Fax: 617-301-9401

Email: info@quanterix.com

Show jobs for this employer

164 articles with Quanterix

  • Company’s SARS-CoV-2 N-Protein Assay measures viral antigen in plasma, dried blood spots and saliva in more than 90 percent of COVID-19 PCR+ positive donors, including those without symptoms

  • Quanterix Corporation (NASDAQ: QTRX) , a company digitizing biomarker analysis to advance the science of precision health, today announced that Chairman, Chief Executive Officer and President, Kevin Hrusovsky, will be presenting at the 10 th Annual SVB Leerink Global Healthcare Conference, being held virtually from February 22 – 26, 2021.

  • Quanterix Corporation announced the closing of its previously announced underwritten public offering of 4,107,142 shares of its common stock at a public offering price of $70.00 per share, including 535,714 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares.

  • Quanterix Corporation, a company digitizing biomarker analysis to advance the science of precision health, announced the pricing of its previously announced underwritten public offering of 3,571,428 shares of its common stock at a public offering price of $70.00 per share.

  • Expects Q4 2020 GAAP revenue of $24-26 million; Non-GAAP revenue of $20-22 million, up approximately 32% over prior Q4 Quanterix to present at J.P. Morgan Healthcare Conference on January 13, 2021 at 3:40 pm ET

  • Antigen test available on Simoa HD-X Analyzer® intended for qualitative detection of the nucleocapsid protein (N protein) from SARS-CoV-2 in nasopharyngeal swab specimens Full suite of Research Use Only Assays Also Available for SARS-CoV-2 Acute and Long Hauler Surveillance and Profiling Studies

  • Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that its Chairman, Chief Executive Officer and President, and Founder of Powering Precision Health (PPH), Kevin Hrusovsky, will be presenting on the Company’s growth and vision for the fifth consecut

  • Detecting the presence of SARS-CoV-2 in asymptomatic individuals has been a challenge not even PCR – the gold standard of testing – can adequately address. Now two companies have developed novel solutions with the sensitivity and specificity needed to provide ample warning.
  • Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced Chairman, Chief Executive Officer and President of Quanterix, and Founder, Powering Precision Health , Kevin Hrusovsky will present at the Contagion Conference being held on Dec. 10, 2020. The conference will focus on COVID-19 testing and will mark the launch of The Virus Project,

  • Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced Chairman, Chief Executive Officer and President, Kevin Hrusovsky will participate in a virtual fireside chat discussion at the Canaccord Medical Technologies and Diagnostics Forum on November 19 at 10:30 a.m., EST. Hrusovsky will also host virtual one-on-one and group meetings with

  • Oct. 6, 2020 19:32 UTC $18.2 million in Phase 2 funding will support the development and scale-up of COVID-19 antigen test based on Simoa ® technology BILLERICA, Mass.--( BUSINESS WIRE )-- Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that it has entered into a Phase 2 contract with the National Institutes of Health (NIH) through its Rapid Acceleration of Diagnostics (RADx℠) initi

  • Company’s ultra-sensitive platform continues to facilitate important advances that harness biomarkers to identify, monitor and validate treatment pathways for Multiple Sclerosis (MS) BILLERICA, Mass.--( BUSINESS WIRE )-- Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that its ultra-sensitive Simoa® technology has been used by leading research teams to power

  • Quanterix Corporation, a company digitizing biomarker analysis to advance the science of precision health, announced the pricing of its previously announced underwritten public offering of 2,651,108 shares of its common stock at a public offering price of $32.00 per share.

  • Quanterix Corporation, a company digitizing biomarker analysis to advance the science of precision health, announced that it has commenced an underwritten public offering of its common stock.

  • Quanterix Corporation (NASDAQ: QTRX) , a company digitizing biomarker analysis to advance the science of precision health, today announced that it will release its financial results for second quarter 2020 after the close of trading on Tuesday, August 4, 2020. Company management will host a conference call at 5:00 p.m., ET to discuss Quanterix’ financial results and provide a business update. The call will be hosted by

  • Findings offer first-time evidence of neuro-axonal damage in mild-to-moderate cases of SARS-CoV-2 and validate serum neurofilament light chain (sNfL) as a highly specific biomarker to measure and monitor damage during and post infection BILLERICA, Mass.--( BUSINESS WIRE )-- Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that quantitative testing using its sN

  • Company’s ultra-sensitive Simoa® technology powers more than 50 posters and presentations on display during this year’s virtual program; attendees can be among the first to experience Simoa p-tau181 assay for improved study of Alzheimer’s disease and visit virtual exhibitor booth

  • Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that Kevin Hrusovsky, Chairman and Chief Executive Officer of Quanterix and Founder of the non-profit Powering Precision Health (PPH), will participate in the MassBio: Possible Talk series on June 26, 2020 at 10 a.m. EDT

  • Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that it will hold its 2020 Annual Meeting of Stockholders (the “Annual Meeting”) virtually due to the public health impact of the coronavirus (COVID-19) pandemic and to prioritize the health and well-being of meeting participants. The Annual Meeting will be held in a virtual-onl

  •   Quanterix’ Simoa Technology Sets New Standard in Protein Detection   New research published in Lab on a Chip demonstrates 100x sensitivity improvement on Simoa; marks significant advancement in sensitivity for industry leading detection platform